Alnylam Pharma (ALNY) Tops Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Alnylam Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Period Activity
April 29, 2021 8:00 AM EDTAchieved First Quarter 2021 Combined Net Product Revenues of $136 Million for ONPATTRO®, GIVLAARI®, and OXLUMO®
Advanced Vutrisiran toward Market with Positive Results from HELIOS-A Phase 3 Study and Submission of New Drug Application (NDA) with U.S. Food and Drug Administration (FDA)
Launched Alnylam P5x25 Strategy to Deliver Transformative Rare and Prevalent Disease Medicines for Patients Around the World Through Sustainable Innovation and Exceptional Financial Performance
Provides Enrollment Update on HELIOS-B Phase 3 Study of Vutrisiran and Now Expects to Complete Enrollment in Late 2021, Ahead of Previous Expectations
... More
